FR2669931B1
(fr)
*
|
1990-11-29 |
1995-03-31 |
Transgene |
Nouveaux variants derives des interferons-alpha et leur procede de production.
|
WO1992009691A1
(fr)
*
|
1990-11-29 |
1992-06-11 |
Institut National De La Recherche Agronomique - I.N.R.A. |
Nouveaux variants derives des interferons de type i, leur procede de production, et leurs applications
|
GB9127250D0
(en)
*
|
1991-12-23 |
1992-02-19 |
Unilever Plc |
Modification
|
FR2700338B1
(fr)
*
|
1993-01-11 |
1995-03-31 |
Transgene Sa |
Nouvelle séquence pro permettant la secrétion de protéines hétérologues à partir d'une cellule de levure.
|
WO1995001431A1
(fr)
*
|
1993-06-29 |
1995-01-12 |
Transgene S.A. |
Famille de peptides appeles xenoxines
|
FR2714908A1
(fr)
*
|
1994-01-11 |
1995-07-13 |
Transgene Sa |
Famille de peptides appelés xénoxines.
|
US5712114A
(en)
*
|
1995-06-06 |
1998-01-27 |
Basf Aktiengesellschaft |
Compositions for expression of proteins in host cells using a preprocollagen signal sequence
|
US5837247A
(en)
*
|
1995-06-16 |
1998-11-17 |
United States Of America As Represented By The Public Health Service National Institutes Of Health |
Chemotactic agents for t-cells
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6469144B1
(en)
|
1996-04-01 |
2002-10-22 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
WO1998013473A1
(en)
|
1996-09-25 |
1998-04-02 |
Vanderbilt University |
Genetically engineered yeast with modified signal peptidase complex
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
CA2293724C
(en)
|
1997-06-05 |
2010-02-02 |
Xiaodong Wang |
Apaf-1, the ced-4 human homolog, an activator of caspase-3
|
JP2002508663A
(ja)
|
1997-06-18 |
2002-03-19 |
ジェネンテク,インコーポレイテッド |
Apo−2DcR
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
DE69839401T2
(de)
|
1997-09-18 |
2009-05-07 |
Genentech Inc., San Francisco |
Dcr3 polypeptid, ein tnfr homolog
|
IL135051A0
(en)
|
1997-10-10 |
2001-05-20 |
Genentech Inc |
Apo-3 ligand polypeptide
|
CA2306183A1
(en)
|
1997-10-29 |
1999-05-06 |
Genentech, Inc. |
Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
|
IL135607A0
(en)
|
1997-10-29 |
2001-05-20 |
Genentech Inc |
Wnt-1 inducible genes
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
ATE410512T1
(de)
|
1997-11-21 |
2008-10-15 |
Genentech Inc |
Plättchen-spezifische antigene und deren pharmazeutische verwendung
|
WO1999036535A1
(en)
|
1998-01-15 |
1999-07-22 |
Genentech, Inc. |
Apo-2 ligand
|
US6727079B1
(en)
|
1998-02-25 |
2004-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
DK1064382T3
(da)
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
PT1076703E
(pt)
|
1998-05-15 |
2007-10-10 |
Genentech Inc |
''utilizações terapêuticas de polipéptido homólogos de il-17''
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
US6545140B1
(en)
*
|
1998-07-13 |
2003-04-08 |
University Of Georgia Research Foundation, Inc. |
DNA encoding an avian beta-defensin and uses thereof
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
CA2450402A1
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Methods and compositions for inhibiting cancer cell growth comprising pro224
|
EP2330198A1
(en)
|
1998-12-23 |
2011-06-08 |
Genentech, Inc. |
IL-1 related polypeptides
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
EP1978029A3
(en)
|
1999-06-15 |
2008-10-15 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
ATE437655T1
(de)
|
1999-06-25 |
2009-08-15 |
Genentech Inc |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
CA2389317A1
(en)
|
1999-10-20 |
2001-04-26 |
Frederic J. De Sauvage |
Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
|
AU2055401A
(en)
|
1999-12-01 |
2001-06-12 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1897947B1
(en)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
CA2395617C
(en)
|
1999-12-30 |
2012-10-30 |
Genencor International, Inc. |
Trichoderma reesei xylanase
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
DE60133884D1
(de)
|
2000-03-24 |
2008-06-19 |
Genencor Int |
Herstellung von sekretierten proteinen durch rekombinante eukaryotische zellen
|
WO2004043361A2
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
EP1272647B1
(en)
|
2000-04-11 |
2014-11-12 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2168980A1
(en)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
PL368972A1
(en)
|
2001-08-29 |
2005-04-04 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
EP2153843B1
(en)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP1571968A4
(en)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
JP2005528905A
(ja)
|
2002-06-07 |
2005-09-29 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
EP2383278A1
(en)
|
2002-07-08 |
2011-11-02 |
Genentech, Inc. |
Method to determine B cell mediated diseases
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
WO2004024072A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
EP2444409A2
(en)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20070042945A1
(en)
|
2002-09-25 |
2007-02-22 |
Genentech, Inc. |
Nouvelles compositions et methods de traitement du psoriasis
|
EP1576137A4
(en)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
US20070048301A1
(en)
|
2002-11-26 |
2007-03-01 |
Bodary-Winter Sarah C |
Compositions and methods for the treatment of immune related diseases
|
SI2407485T1
(sl)
|
2003-02-01 |
2016-09-30 |
Tanox, Inc. |
Visoko afinitetna anti-humana protitelesa IgE
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
KR20180014881A
(ko)
|
2003-05-30 |
2018-02-09 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
CN1802386B
(zh)
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
US7097993B2
(en)
|
2003-06-25 |
2006-08-29 |
Wisconsin Alumni Research Foundation |
Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
|
PL2784084T3
(pl)
|
2003-07-08 |
2020-03-31 |
Genentech, Inc. |
Przeciwciała antagonistyczne wobec heterologicznych polipeptydów IL-17A/F
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
CA2550447A1
(en)
|
2003-12-19 |
2005-07-07 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies
|
TR201815885T4
(tr)
|
2004-01-07 |
2018-11-21 |
Novartis Vaccines & Diagnostics Inc |
M-csf spesifik monoklonal antikorlar ve bunların kullanımı.
|
NZ550102A
(en)
|
2004-02-24 |
2010-10-29 |
Univ California |
Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
|
SI1730191T1
(sl)
|
2004-03-30 |
2011-11-30 |
Glaxo Group Ltd |
Imunoglobulin-vezavni hOSM
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
EP2361931B1
(en)
|
2004-07-20 |
2017-12-06 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP2230517A1
(en)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
AU2006255686A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
EP1913027B1
(en)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf specific monoclonal antibody and uses thereof
|
CA2619577A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
SI1948798T1
(sl)
|
2005-11-18 |
2015-09-30 |
Glenmark Pharmaceuticals S.A. |
Anti-alfa 2 integrin protitelesa in njihova uporaba
|
US20090293137A1
(en)
|
2005-11-21 |
2009-11-26 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
WO2007109376A2
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
PT2656841T
(pt)
|
2006-03-27 |
2016-09-28 |
Univ California |
Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
|
KR101600230B1
(ko)
|
2006-03-29 |
2016-03-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
디아릴티오히단토인 화합물
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
EP2082645A1
(en)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
ES2531933T3
(es)
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
EP2420252A1
(en)
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-specific antibody and uses thereof
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
US20080254512A1
(en)
|
2006-11-02 |
2008-10-16 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
WO2008100805A2
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
CA2690124A1
(en)
|
2007-06-07 |
2008-12-18 |
Genentech, Inc. |
C3b antibodies and methods for the prevention and treatment of complement-associated disorders
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
CN111499748A
(zh)
|
2007-07-16 |
2020-08-07 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
EP2220050A2
(en)
|
2007-10-26 |
2010-08-25 |
The Regents Of The University Of California |
Diarylhydantoin compounds as androgen receptor modulators
|
JP2011503094A
(ja)
|
2007-11-08 |
2011-01-27 |
ジェネンテック, インコーポレイテッド |
抗b因子抗体およびそれらの使用
|
AU2008321016B2
(en)
|
2007-11-12 |
2013-03-28 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
WO2009092805A1
(en)
|
2008-01-24 |
2009-07-30 |
Novo Nordisk A/S |
Humanized anti-human nkg2a monoclonal antibody
|
EP3269737B1
(en)
|
2008-01-31 |
2024-06-19 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JP2011517314A
(ja)
|
2008-02-14 |
2011-06-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
|
CA2718878A1
(en)
|
2008-03-10 |
2009-09-17 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
KR101855381B1
(ko)
|
2008-04-09 |
2018-05-09 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
AU2009312532B2
(en)
|
2008-11-06 |
2013-05-16 |
Ichnos Sciences SA |
Treatment with anti-alpha2 integrin antibodies
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010124163A2
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
CA2762302A1
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2488643A4
(en)
|
2009-10-15 |
2013-07-03 |
Hoffmann La Roche |
CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011060246A2
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
SG182590A1
(en)
|
2010-01-28 |
2012-08-30 |
Glaxo Group Ltd |
Cd127 binding proteins
|
ES2668380T3
(es)
|
2010-02-16 |
2018-05-17 |
Aragon Pharmaceuticals, Inc. |
Moduladores de receptores de andrógenos y sus usos
|
CA2790329A1
(en)
|
2010-02-18 |
2011-08-25 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind il-23
|
JP5972176B2
(ja)
|
2010-02-23 |
2016-08-17 |
サノフイ |
抗アルファ2インテグリン抗体及びそれらの使用
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
EP3424949A1
(en)
|
2010-04-13 |
2019-01-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind pcsk9
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
CA3209878A1
(en)
|
2010-05-25 |
2011-12-01 |
Genentech, Inc. |
Methods of purifying polypeptides
|
EP2576615B1
(en)
|
2010-05-26 |
2016-03-30 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
US9169329B2
(en)
|
2010-06-01 |
2015-10-27 |
Ludwig Institute For Cancer Research |
Antibodies directed to the receptor tyrosine kinase c-Met
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
KR101768118B1
(ko)
|
2010-06-25 |
2017-08-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
기도 감염의 치료를 위한 방법 및 약학 조성물
|
WO2012010635A1
(en)
|
2010-07-22 |
2012-01-26 |
Glaxosmithkline Biologicals S.A. |
Novel antigen binding proteins
|
WO2012021786A2
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
EP2611465A4
(en)
|
2010-08-31 |
2014-06-04 |
Theraclone Sciences Inc |
NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
|
CA2811403A1
(en)
|
2010-09-15 |
2012-03-22 |
Aligna Technologies, Inc. |
Bioproduction of aromatic chemicals from lignin-derived compounds
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR101631740B1
(ko)
|
2010-10-08 |
2016-06-17 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 단편의 진단학적 및 치료학적 용도
|
EP2624856B1
(en)
|
2010-10-08 |
2016-12-14 |
Shanghai Kexin Biotech Co., Ltd |
Moesin fragments for use in the diagnosis of immune thrombocytopenia
|
JP5868410B2
(ja)
|
2010-10-08 |
2016-02-24 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
再生不良性貧血と関連しているモエシン断片
|
CA2814023C
(en)
|
2010-10-08 |
2018-01-16 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments and uses thereof
|
KR101687060B1
(ko)
|
2010-10-08 |
2016-12-15 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 조절제 및 그의 용도
|
RS55161B1
(sr)
|
2010-11-04 |
2017-01-31 |
Boehringer Ingelheim Int |
Anti-il-23 antitela
|
WO2012083370A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
CN103380143B
(zh)
|
2010-12-22 |
2016-01-06 |
百时美施贵宝公司 |
结合il-23的基于纤连蛋白的支架结构域蛋白质
|
WO2012112489A2
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012122528A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
CN103533929A
(zh)
|
2011-03-15 |
2014-01-22 |
特罗科隆科学有限公司 |
用于流行性感冒的治疗和诊断的组合物和方法
|
HUE033008T2
(hu)
|
2011-04-13 |
2017-11-28 |
Bristol Myers Squibb Co |
FC fúziós proteinek, amelyek tartalmaznak új linkereket
|
EP2714735B1
(en)
|
2011-06-03 |
2021-07-21 |
XOMA Technology Ltd. |
Antibodies specific for tgf-beta
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
US20140315274A1
(en)
*
|
2011-11-11 |
2014-10-23 |
Novozymes A/S |
Methods For Production of Archeae Protease in Yeast
|
KR20200110476A
(ko)
|
2011-11-16 |
2020-09-23 |
베링거 인겔하임 인터내셔날 게엠베하 |
항 il-36r 항체
|
CA2857168C
(en)
|
2011-12-01 |
2020-10-27 |
Protevobio, Inc. |
Protein inhibitors to complement and vegf pathways and methods of use thereof
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
JP6211597B2
(ja)
|
2012-05-01 |
2017-10-11 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
新規抗体
|
EP2844284A1
(en)
|
2012-05-03 |
2015-03-11 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
DK3564258T3
(da)
|
2012-09-13 |
2021-06-21 |
Bristol Myers Squibb Co |
Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
|
SI3305285T1
(sl)
|
2012-09-26 |
2021-03-31 |
Aragon Pharmaceuticals, Inc. |
Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
WO2014088934A1
(en)
|
2012-12-07 |
2014-06-12 |
Danisco Us Inc. |
Compositions and methods of use
|
BR112015013068A2
(pt)
*
|
2012-12-07 |
2017-09-12 |
Danisco Us Inc |
composições e métodos de uso
|
US9879245B2
(en)
|
2012-12-07 |
2018-01-30 |
Danisco Us Inc. |
Polypeptides having beta-mannanase activity and methods of use
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
ES2645634T3
(es)
|
2013-02-12 |
2017-12-07 |
Bristol-Myers Squibb Company |
Métodos de replegado de proteínas a elevado pH
|
JP6606059B2
(ja)
|
2013-03-13 |
2019-11-13 |
ジェネンテック, インコーポレイテッド |
酸化還元製剤
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
AU2014243700B2
(en)
|
2013-03-13 |
2019-01-24 |
Genentech, Inc. |
Formulations with reduced oxidation
|
DK2968461T3
(da)
|
2013-03-13 |
2022-12-19 |
Genzyme Corp |
Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
AR095348A1
(es)
|
2013-03-15 |
2015-10-07 |
Genentech Inc |
Medios de cultivo celular y métodos de producción de anticuerpos
|
CN105121628B
(zh)
|
2013-03-15 |
2020-03-24 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
DK3611180T3
(da)
|
2013-03-15 |
2022-02-28 |
Biomolecular Holdings Llc |
Hybrid immunoglobulin indeholdende ikke-peptidyl-binding
|
SG11201507429TA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
TWI714022B
(zh)
|
2013-09-27 |
2020-12-21 |
美商建南德克公司 |
抗-pdl1抗體調配物
|
EP3069137A1
(en)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organic compounds
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
MX2016007887A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
|
BR112016014731A2
(pt)
|
2014-01-31 |
2017-09-19 |
Boehringer Ingelheim Int |
Anticorpos anti-baff
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
SG10201807877TA
(en)
|
2014-03-14 |
2018-10-30 |
Daniel Capon |
Hybrid immunoglobulin containing non-peptidyl linkage
|
EP3647322B1
(en)
|
2014-03-20 |
2021-10-20 |
Bristol-Myers Squibb Company |
Stabilized fibronectin based scaffold molecules
|
SG11201607820QA
(en)
|
2014-03-20 |
2016-10-28 |
Bristol Myers Squibb Co |
Serum albumin-binding fibronectin type iii domains
|
RU2710551C2
(ru)
|
2014-03-25 |
2019-12-27 |
Дженентек, Инк. |
Способы приготовления полоксамера для применения в клеточной культуральной среде
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
EP3201332A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
US20170211053A1
(en)
|
2014-09-30 |
2017-07-27 |
Danisco Us Inc. |
Compositions comprising beta mannanase and methods of use
|
EP3201333A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
US20170233707A1
(en)
|
2014-09-30 |
2017-08-17 |
Danisco Us Inc |
Compositions comprising beta-mannanase and methods of use
|
US20170211054A1
(en)
|
2014-09-30 |
2017-07-27 |
Dansico Us Inc. |
Compositions comprising beta mannanase and methods of use
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3702367B1
(en)
|
2014-11-25 |
2024-05-15 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
US10954282B2
(en)
|
2014-12-09 |
2021-03-23 |
Wentao Zhang |
NBP158 and uses thereof
|
WO2016100825A1
(en)
|
2014-12-18 |
2016-06-23 |
Danisco Us Inc |
Engineered multifunctional enzymes and methods of use
|
EP3234119A1
(en)
|
2014-12-18 |
2017-10-25 |
Danisco US Inc. |
Engineered multifunctional enzymes and methods of use
|
JP6621478B2
(ja)
|
2014-12-19 |
2019-12-18 |
アルカーメス,インコーポレイテッド |
一本鎖Fc融合タンパク質
|
AU2016215227A1
(en)
|
2015-02-04 |
2017-09-21 |
Assistance Publique-Hopitaux De Paris |
Mutant smoothened and methods of using the same
|
IL307578A
(en)
|
2015-02-04 |
2023-12-01 |
Boehringer Ingelheim Int |
Methods for treating inflammatory diseases
|
CN107530425A
(zh)
|
2015-04-14 |
2018-01-02 |
勃林格殷格翰国际有限公司 |
治疗疾病的方法
|
WO2016171980A1
(en)
|
2015-04-24 |
2016-10-27 |
Bristol-Myers Squibb Company |
Polypeptides targeting hiv fusion
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
KR20180056701A
(ko)
|
2015-09-23 |
2018-05-29 |
브리스톨-마이어스 스큅 컴퍼니 |
패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인
|
CN108884147B
(zh)
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
|
SG11201804951SA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Use of tryptophan derivatives for protein formulations
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
EP3974451A3
(en)
|
2016-04-15 |
2022-07-06 |
Boehringer Ingelheim International GmbH |
Methods of treating inflammatory diseases
|
KR102397783B1
(ko)
|
2016-06-01 |
2022-05-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-l1 결합 폴리펩티드에 의한 pet 영상화
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
MA45186A
(fr)
*
|
2016-06-03 |
2019-04-10 |
Janssen Biotech Inc |
Domaines de fibronectine de type iii se liant à l'albumine sérique
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
US20180105588A1
(en)
|
2016-10-14 |
2018-04-19 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018183173A1
(en)
|
2017-03-27 |
2018-10-04 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
TW201842929A
(zh)
|
2017-05-03 |
2018-12-16 |
美商必治妥美雅史谷比公司 |
結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
JOP20200076A1
(ar)
|
2017-10-16 |
2020-04-30 |
Aragon Pharmaceuticals Inc |
مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
|
JP2021507717A
(ja)
|
2017-12-18 |
2021-02-25 |
ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッドViiv Healthcare Uk (No.5) Limited |
抗原結合性ポリペプチド
|
DK3743088T3
(da)
|
2018-01-26 |
2022-12-19 |
Hoffmann La Roche |
IL-22 Fc-sammensætninger og fremgangsmåder til anvendelse
|
EP3743437A1
(en)
|
2018-01-26 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Il-22 fc fusion proteins and methods of use
|
CA3091139A1
(en)
|
2018-02-21 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with il-22 fc fusion proteins
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
KR20210024550A
(ko)
|
2018-06-23 |
2021-03-05 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
|
CA3101469A1
(en)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
KR20210042936A
(ko)
|
2018-08-08 |
2021-04-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
SG11202103124WA
(en)
|
2018-10-23 |
2021-04-29 |
Glycardial Diagnostics S L |
Antibodies specific for glycosylated apoj and uses thereof
|
EA202192405A1
(ru)
|
2019-03-08 |
2022-01-13 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Составы антител против il-36r
|
CR20210559A
(es)
|
2019-05-09 |
2021-12-23 |
Boehringer Ingelheim Int |
Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
CN111018960B
(zh)
*
|
2019-12-04 |
2021-09-10 |
中国农业科学院饲料研究所 |
一种抗菌肽id13及其制备方法和应用
|
EP4077378A1
(en)
|
2019-12-20 |
2022-10-26 |
NovaRock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
WO2021174045A1
(en)
|
2020-02-28 |
2021-09-02 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
AU2021248941A1
(en)
|
2020-03-31 |
2022-11-17 |
Repertoire Immune Medicines, Inc. |
Barcodable exchangeable peptide-MHC multimer libraries
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
CR20220596A
(es)
|
2020-05-26 |
2023-01-23 |
Boehringer Ingelheim Int |
Anticuerpos anti-pd-1
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022087154A1
(en)
|
2020-10-20 |
2022-04-28 |
Repertoire Immune Medicines, Inc. |
Mhc class ii peptide multimers and uses thereof
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
CN117062836A
(zh)
|
2021-02-05 |
2023-11-14 |
勃林格殷格翰国际有限公司 |
抗il1rap抗体
|
US11572412B2
(en)
|
2021-06-04 |
2023-02-07 |
Boehringer Ingelheim International Gmbh |
Anti-SIRP-alpha antibodies
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
AR128065A1
(es)
|
2021-12-22 |
2024-03-20 |
Cdr Life Ag |
Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
|
EP4238988A1
(en)
|
2022-03-01 |
2023-09-06 |
Consejo Superior De Investigaciones Científicas |
Antibodies against sars-cov-2 and uses thereof
|
WO2023196995A1
(en)
|
2022-04-07 |
2023-10-12 |
Repertoire Immune Medicines, Inc. |
T cell receptor multimers and uses thereof
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|